During pregnancy, the bone hormone osteocalcin is produced by the mother; it crosses the placenta, to reach the fetus, where it promotes the formation of the hippocampus and the development of spatial learning and memory. Postnatally, osteocalcin crosses the blood-brain barrier (BBB), to act in various regions of the brain, including the hippocampus, where it causes changes in brain chemistry that help prevent anxiety and depression and improve spatial learning and memory.

NEW YORK, NY (September 26, 2013) — Researchers from Columbia University Medical Center (CUMC) have found that the skeleton, acting through the bone-derived hormone osteocalcin, exerts a powerful influence on prenatal brain development and cognitive functions such as learning, memory, anxiety, and depression in adult mice. Findings from the mouse study could lead to new approaches to the prevention and treatment of neurologic disorders. The study was published today in the online edition of Cell.

“The brain is commonly viewed as an organ that influences other organs and parts of the body, but less often as the recipient of signals coming from elsewhere, least of all, the bones,” said study leader Gerard Karsenty, MD, PhD, Paul A. Marks Professor of Genetics and Development, professor of medicine, and chair of the Department of Genetics and Development.

“In an earlier study, we showed that the brain is a powerful inhibitor of bone mass accrual,” he said. “This effect was so powerful that it immediately raised the question, ‘Does the bone signal back to the brain to limit this negative influence?’ ‘If so, what signals does it use and how do they work?’”

Dr. Karsenty suspected that osteocalcin, a hormone recently identified by his lab and secreted by osteoblasts, might be involved in such bone-to-brain signaling. Earlier studies had shown that osteocalcin affects a variety of processes, such as energy expenditure, glucose balance, and male fertility. “Since most hormones influence a range of physiological processes, it was reasonable to assume that the endocrine functions of osteocalcin were even broader than what was already known,” he said.

To determine whether osteocalcin did indeed play a role in the brain, Dr. Karsenty and his team studied “osteocalcin-null” mice (mice that have been genetically engineered to not produce any osteocalcin). Using these mice, they were able to show unambiguously that osteocalcin can cross the blood-brain barrier; binds to neurons in the brainstem, midbrain, and hippocampus (which is responsible for learning and memory); promotes the birth of neurons; and increases the synthesis of several neurotransmitters, including serotonin, dopamine, and catecholamine. They also found that osteocalcin-null mice had abnormally small hippocampi, a part of the brain involved in memory.

The researchers then hypothesized that the changes in neurotransmitter synthesis should alter the animals’ behavior. In a series of behavioral tests, they confirmed that osteocalcin-null mice exhibit increased anxiety and depression-like behaviors, as well as impaired learning and memory, compared with normal mice.

These changes are similar to those seen in the aging population. “As we age, bone mass decreases, and the production of osteocalcin probably does, too,” said Dr. Karsenty. “We’re currently looking into this. It is not inconceivable that treatments that boost osteocalcin levels or stimulate osteocalcin receptors could help counter the cognitive effects of aging and aging-related diseases such as Alzheimer’s.”

When adult osteocalcin-null mice were infused with osteocalcin, their anxiety and depression did decrease, “but the infusions didn’t affect learning and memory or the size of the hippocampus,” said Dr. Karsenty. “This was perplexing, so we did another experiment—a postnatal knockout of osteocalcin (a genetically engineered model in which the synthesis of osteocalcin is blocked after birth). These mice were anxious and depressed but had normal memory and hippocampus structure. The unavoidable conclusion of the two experiments was that osteocalcin must act during development.” This led to the second part of their study.

In subsequent experiments, the researchers showed that osteocalcin crosses the placenta from mother to fetus and that this maternal pool of osteocalcin is necessary for formation of the hippocampus and the establishment of memory. Lastly, they showed that once-a-day injections of osteocalcin in osteocalcin-null mothers during pregnancy could prevent the development of behavioral abnormalities in their offspring.

“This finding could explain some of the effects observed in children born from undernourished mothers who develop, with an unusually high frequency, metabolic and psychiatric disorders just as osteocalcin-null mice do,” said Dr. Karsenty. “Malnutrition decreases the activity of bone cells; as a result, undernourished mothers have low bone mass, which affects osteocalcin production. This has clinical relevance even today, in developing countries, where maternal malnutrition is still common.”

Any therapies related to osteocalcin are still years away, however, he added.

The paper is titled, “Maternal and offspring pools of osteocalcin influence brain development and functions.” The other contributors are Franck Oury (CUMC), Lori Khrimian (CUMC), Christine. A. Denny (CUMC), Antoine Gardin (formerly with CUMC), Alexandre Chamouni (CUMC), Nick Goeden (University of Southern California, Los Angeles, CA), Yung-yu Huang (CUMC), Hojoon Lee (CUMC), Prashanth Srinivas (CUMC), Xiao-Bing Gao (Yale University School of Medicine), Shigetomo Suyama (Yale), Thomas Langer (Sanofi Deutchland GMBH, Frankfurt am Main, Germany), J. John Mann (CUMC), Tamas. L. Horvath (Yale), and Alexandre Bonnin (University of Southern California).

Columbia University has filed for patents relating to osteocalcin and its use to treat a variety of conditions. The authors declare no financial or other conflicts of interests.

The study was supported by grants from the NIA, NIDDK, and NIAMS (5 P01 AG032959 and 5 R01 AR045548 ), Sanofi Aventis, the Human Frontier Scientific Program, an NIH Director’s Pioneer Award, and an Ellison Medical Foundation Senior Scholar Award.

####

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.